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Summary 
Lipid bodies, hpid-rich cytoplasmic inclusions,  are characteristically  abundant in vivo in leukocytes 
associated with inflammation. Because lipid bodies are potential reservoirs of esterified  arachido- 
hate and sites at which eicosanoid-forming enzymes may localize, we evaluated mechanisms of 
lipid body formation in neutrophils (PMN). Among receptor-mediated agonists, platelet-activat- 
ing factor (PAF), but not C5a, formyl-methyl-phenylalanine, interleukin 8, or leukotriene (LT) 
B4, induced the rapid formation of  lipid bodies in PMN. This action of PAF was receptor medi- 
ated, as it was dose dependently inhibited by the PAF receptor antagonist WEB 2086 and blocked 
by pertussis  toxin. Lipid body induction by PAF required 5-lipoxygenase (LO) activity and was 
inhibited by the 5-1ipoxygenase-activating protein antagonist MK 886 and the 5-LO inhibitor 
zileuton, but not by cyclooxygenase inhibitors. Corroborating the dependency of PAF-induced 
lipid body formation on 5-LO, PMN  and macrophages from wild-type mice, but not from 
5-LO genetically deficient mice, formed lipid bodies on exposure to PAF both in vitro and in 
vivo within the pleural cavity. The 5-LO product inducing lipid body formation was not LTB4 
but was 5(S)-hydroxyeicosatetraenoic acid [5(S)-HETE], which was active at 10-fold lower con- 
centrations than PAF and was also inhibited by pertussis toxin but not by zileuton or WEB 2086. 
Furthermore, 5-HETE was equally effective in inducing lipid body formation in both wild-type 
and 5-LO genetically deficient mice. Both PAF- and 5(S)-HETE-induced lipid body formation 
were inhibited by the protein kinase C  (PKC) inhibitors staurosporine and chelerythrine, the 
phosphotipase C  (PLC) inhibitors D609 and U-73122, and by actinomycin D  and cyclohexi- 
mide. Prior stimulation of human PMN with PAF to form lipid bodies enhanced eicosanoid 
production in response to submaximal stimulation with the calcium ionophore A23187; and 
the levels of both prostaglandin (PG) E 2 and LTB  4 correlated with the number of lipid bodies. 
Furthermore, pretreatment of cells with actinomycin D  or cycloheximide inhibited not only the 
induction of lipid body formation by PAF, but also  the PAF-induced "priming" for enhanced 
PGE  2 and LTB  4 in PMN.  Thus, the  compartmentalization of lipids to form lipid bodies in 
PMN is dependent on specific cellular responses that can be PAF receptor mediated, involves 
signaling  through 5-LO to form 5-HETE and then through PKC and PLC, and requires new 
protein synthesis. Since increases in lipid body numbers correlated with priming for enhanced 
PGE  2 and LTB4 production in PMN, the induction of lipid bodies may have a role in the for- 
mation of eicosanoid mediators by leukocytes involved in inflammation. 
E 
icosanoids, including PG, thromboxanes, leukotrienes 
(LT)  1,  hydroxyeicosatetraenoic acids  (HETE), and li- 
poxins,  are  enzymatically formed oxidative derivatives of 
1Abbreviations used in this paper: FLAP, 5-1ipoxygenase-activating  protein; 
5-oxo-ETE,  5-oxo-eicosatetraenoic acid; HETE, hydroxyeicosatet- 
raenoic acid; LO, lipoxygenase;  LT, leukotriene;  PAF, platelet-actlvating 
factor; PKC, protein kinase C; PLC, phospholipase  C. 
arachidonic acid that have a wide range of biological activ- 
ities, including roles as paracrine mediators of inflammation 
(1, 2). Arachidonate is released by the actions ofphosphoh- 
pases from arachidonyl phospholipids, which may reside in 
various membranes within cells. In addition to membranes, 
another hpid-bearing domain in cells  can be hpid bodies, 
which are lipid-rich cytoplasmic inclusions. Although lipid 
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with appropriate fi  afion and staining, lipid bodies have been 
recognized to be prominent in leukocytes at sites  of natural 
and experimental inflammation. For instance, increased lipid 
body numbers  have been noted in PMN  from inflamma- 
tory arthritis (3), from bronchoalveolar lavage of  patients with 
acute respiratory distress  syndrome (4), and from elicited rab- 
bit peritoneal  exudates  (5).  Lipid bodies can be sites  of es- 
terified  arachidonate  localization  in  cells  including  PMN 
and eosinophils  (6,  7).  In addition,  PG endoperoxide syn- 
thase  has been localized to lipid bodies  in several  types of 
leukocytes and other cells  (8-10). Although lipid bodies are 
prominent in cells associated with inflammation and might 
have roles in the  oxidative  metabolism  of arachidonate  to 
form eicosanoids, little is known about how these cytoplas- 
mic structures form. 
We have evaluated the capacity of several agonists, known 
to stimulate PMN through specific cognate G protein-linked 
plasma membrane receptors,  to elicit lipid body formation. 
Of these  PMN  agonists,  platelet-activating  factor  (PAF) 
specifically induces lipid body formation; and the actions of 
PAF are receptor mediated, obligately dependent on 5-1ipoxy- 
genase (LO) activation, as well as dependent on subsequent 
stimulation  of protein  kinase  C  (PKC),  phospholipase  C 
(PLC), and new protein synthesis.  The PAF-elicited com- 
partmentalization  oflipids to form new lipid bodies is asso- 
ciated with enhanced capacity for eicosanoid generation, sug- 
gesting  that  the  cellular  responses  leading  to  lipid  body 
formation may be important in the formation of eicosanoid 
mediators of inflammation. 
Materials and Methods 
LTB4, rhC5a, FMLP, aspirin, indomethacin, ibuprofen,  piroxi- 
cam,  salicylic acid  (sodium salt), nordihydroguaiaretic acid,  and 
cycloheximide  were  obtained  from  SigIna  Chemical  Co.  (St. 
Louis,  MO).  PAF  (1-O-hexadecyl-2-acetyl-sn-glyceryl-3-phos- 
phorylcholine),  lyso-PAF  (1-O-alkyl-sn-glyceryl-3-phosphoryl- 
chohne),  staurosporine,  chelerythrine,  actinomycin D,  pertussis 
toxin, and A23187 were from Calbiochem Novabiochem Corp. 
(La Jolla,  CA).  5(S)-HETE  [5(S)-hydroxy-6,8,11,14-eicosatet- 
raenoic  acid]  and  5(R)-HETE  [5(R)-hydroxy-6,8,11,14-eico- 
satetraenoic  acid]  were from Cayman Chemical Co.  Inc.  (Ann 
Arbor, MI). The PLC inhibitors  D609 and U-73122, and 5-oxo- 
6,8,11,14-eicosatetraenoic  acid (5-oxo-ETE) were from BIOMOL 
Research Laboratories Inc. (Plymouth Meeting, PA). The follow- 
ing were generous gifts: WEB 2086 from Boehringer-Ingelheim 
(Ingelheim, Germany), zileuton from Abbott Laboratories  (North 
Chicago, IL), CP-105,696 from Dr. Henry Showell (Pfizer Cen- 
tral  Research,  Groton,  CT),  and MK886  from Dr. Jilly  Evans 
(Merck Frosst, Point Claire-Dorval, Quebec, Canada). 
Human Neutrophil Purification.  Fresh human blood was obtained 
by venipuncture from healthy adult volunteers and collected into 
acidified citrate. After addition of 6% dextran 70 (McGaw, Irvine, 
CA), RBC were allowed to sediment for 1 h at room tempera- 
ture.  The leukocyte-rich supernatant was overlaid  onto an equal 
volume of Ficoll-Paque  (Pharmacia  Biotechnology Inc., Piscat- 
away,  NJ),  and centrifuged at 400 g for 20 min.  PMN  (>95% 
pure, rest being eosinophils)  were recovered from the pellet and 
washed  in  CaZ+/Mg2+-free  HBSS.  Residual  RBC  were  lysed 
with hypotonic saline. 
Investigations with Mouse Leukocytes.  5-LO gene-targeted mice 
(5-LO-/-;  Dr.  Beverly Koller,  University  of North  Carolina, 
Chapel Hill,  NC)  and control wild-type mice  (5-LO  +/+) were 
generated as described  (11). All experiments were carried out with 
male  8-12-wk-old mice.  Bone marrow,  from both femurs and 
humeri, was obtained by lavaging the marrow cavity with 3 ml of 
RPMI  containing  heparin  (20  IU/ml).  After  dissociating  the 
bone  marrow  with  a  transfer  pipette,  the  cell  suspension  was 
overlaid onto an equal volume of Ficoll-Paque and centrifuged at 
400 g for 20 man. The supematant was aspirated,  and the pellet, 
rich  in  granulocytes  (>90%  pure),  was  resuspended  in  Ca-*+/ 
Mg2+-free HBSS. 
Pleurisy was induced in methoxyfluorane anesthetized  mice by 
intrathoracic injection of PAF (1 p,g/cavity)  in a final volume of 
100 pA. Each experiment included an equivalent number of con- 
trol animals receiving the same volume of sterile Ca2+/Mg2+-free 
HBSS. The animals were killed in CO2 4 h after the intrathoracic 
injection of PAF or buffer.  The thoracic cavity was washed with 
1 ml ofheparinized CaZ+/MgZ+-free  HBSS (10 IU/ml). 
Lipid Body Induction and Treatments.  PMN (106 cells/ml)  were 
incubated with varying concentrations  ofPAF, lyso-PAF, 5-HETE, 
5-oxo-ETE, C5a, LTB  4, FMLP, IL-8, or vehicle at 37~  in a 5% 
CO2 95% 02 atmosphere; and after incubation periods (5 man-4 h), 
PMN  (10S/slide)  were  cytocentrifuged (550  rpm,  5  rain)  onto 
glass shdes. During inhibitory studies, PMN were pretreated  for i h 
with varying concentrations of receptor antagonist,  enzyme in- 
hibitors, protein synthesis inhibitors,  or vehicle as indicated.  When 
PKC inhibitors  were used, the preincubation time was reduced to 
30 rain to avoid toxic effect to the cells. The cell viability, deter- 
mined by trypan blue  dye exclusion at the end of each experi- 
ment, was always >90%. Stock solutions for A23187, WEB 2086, 
D609, U-73122, zileuton, indomethacin, CP-105,696, actinomy- 
cin D, and MK886 were prepared in DMSO and stored at -20~ 
Aliquots were diluted in Ca2+/MgZ+-free HBSS to the indicated 
concentration immediately before use. The final DMSO concen- 
tration was always <0.1% and had no effect on lipid body num- 
bers.  Ibuprofen, aspirin,  piroxicam,  salicylic acid,  staurosporine, 
chelerythrine, cycloheximide, and pertussis toxin were diluted in 
Ca2+/Mg2+-free HBSS. 
Leukocyte Counts.  Blood or pleural samples were diluted in Turk 
fluid (2% acetic acid) for total leukocyte counts in a hemocytom- 
eter.  Differential  analyses were  performed  on  cytocentrifuged 
samples or blood smears stained  with Diff-Quik (Baxter  Health- 
care Corp., Miami, FL). 
Lipid Body Staining and Enumeration.  Slides, while  still moist, 
were fixed in 3.7% formaldehyde in Ca2+/Mga+-free HBSS, pH 
7.4,  rinsed  in 0.1  M  cacodylate buffer,  pH 7.4,  stained  in  1.5% 
OsO  4 (30 rain),  rinsed in dH20, immersed in 1.0% thiocarbohy- 
drazide  (5 rain),  rinsed in 0.1  M  cacodylate buffer,  restained  in 
1.5%  OsO4  (3  min),  rinsed  in  dH20,  and  then  dried  and 
mounted. The morphology of fixed cells was observed, and lipid 
bodies were  enumerated by phase  contrast microscopy with  an 
objective  lens  at  a  magnification  of 100  in  50  consecutively 
scanned PMN. 
PGE  2 and LTB  4 Measurement.  Human PMN (5  ￿  106 cells/ 
5  ml)  were  stimulated  with  PAF  (10-8-10 -6 M)  or vehicle  at 
37~  for 5 or 60 min for lipid body formation. After incubations, 
samples were taken for lipid  body enumeration and PMN were 
washed in Ca2+/Mg2+-free  HBSS. PMN were resuspended in 1 ml 
of HBSS containing Ca  2+/Mg  2+ and then stimulated with A23187 
(0.5  ~M)  for 15  man.  P,.eactions were stopped on ice,  and the 
1516  Mechanisms of Lipid Body Formation in PMN samples were centrifuged at 500 g for 10 min at 4~  PGE2 and 
LTB4 in the supematants were assayed by ELISA according to the 
manufacturer's instructions (Cayman Chemical Co., Inc.). 
Statistical Analysis.  Results were  expressed  as  mean +  SEM 
and were  analyzed statistically by means of analysis of variance 
followed by the  Newman-Keuls-Student test  with the  level of 
significance set at P  <0.05.  Correlation coefficients were deter- 
mined  by  linear  regression,  and  correlation  analysis  was  per- 
formed by Fisher's r to z  transformation with the level of signifi- 
cance set at P <0.05. 
Results 
Agonist Induction of Lipid Body Formation in Human  PMN. 
Several PMN  agonists, known to act via specific G  protein- 
linked receptors,  were  evaluated for their ability to stimu- 
late  lipid  body  formation.  LTB  4  (10-9-10 -7  M),  C5a 
(10-9-10 -7 M), IL-8 (1-25 ng/ml), and FMLP (10-8-10 -6 
M),  in concentrations that significantly induce chemotaxis 
in human PMN  (12),  failed to  cause lipid bodies to  form 
(Table  1).  In  contrast,  PAF  stimulated  a  dose-dependent 
induction of lipid bodies in PMN  in vitro  (Fig.  1 A). The 
PAF induction of lipid body formation was significant within 
15 rain, maximal at 1-2 h, and decreased thereafter  (Fig.  1 
B).  Several findings indicated the actions of PAF were  re- 
ceptor mediated. First, lyso-PAF failed to induce lipid body 
formation (Fig.  1 A). Second, the PAF receptor antagonist, 
WEB  2086, dose dependently inhibited PAF-induced lipid 
body formation  (Fig.  2),  with an approximate  ICs0 of 0.4 
p~M. Moreover, prior treatment of cells with pertussis toxin 
(100  ng/ml,  1  h  before  PAF)  completely prevented PAF- 
induced lipid body formation (Fig. 2). 
Requirement for 5-L0 Activation in PAF-induced Lipid Body 
Formation.  The  possibility that  eicosanoids  might  be  in- 
volved in mediating PAF-initiated signaling to form lipid bod- 
ies was evaluated with a variety ofinhibitors. Four cycloox- 
ygenase inhibitors (mean +  SEM lipid bodies/PMN:  13.2  + 
Table  1.  Effect  of Agonists Acting on G Protein-linked Receptors 
on PMN Lipid Body Formation 
Stimuli  Dose  Lipid bodies 
(mean + SEM)/PMN 
C5a  0  3.9 +  0.3 
10 -9 M  3.9 +  0.2 
10 -s M  4.0 +  0.2 
10 -7 M  3.7 +  0.2 
LTB4  0  3.9 -  0.3 
10 -9 M  3.9 +  0.2 
10 -8 M  4.0 +_ 0.2 
10  -7 M  4.0 +  0.3 
FMLP  0  3.9 +  0.3 
10 -~ M  4.0 -+ 0.3 
10 -7 M  4,0 +  0.3 
10 -6 M  4.0 +  0.3 
IL-8  0  1.4 4- 0.2 
1 ng/ml  1.8 +  0.2 
5 ng/ml  1.7 -----  0.2 
25 ng/ml  2.0 +  0.2 
PMN (10  6 cells/ml)  were treated  with each  agonist for 1 h at 37~ 
Results are means +  SEM from 50 consecutively  counted PMN. Data 
from one individual donor are representative of three experiments with 
similar results. 
0.6  with  1  p~g/ml  of indomethacin;  13.5  +  0.5  with  10 
~g/ml of aspirin; 12.3  +  0.4 with  10 I~g/ml ofibuprofen; 
13.2  +  0.5 with 10 p~g/ml ofpiroxicam vs.  12.2  +  0.5 for 
vehicle-treatment alone, NS) and salicylic acid (13.5  +  0.4 
with  10 p,g/ml of salicylic acid vs.  12.2  •  0.5 for vehicle- 
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Figure  1.  Dose  response  (A) 
and  time  course  (B)  for  PAF- 
induced lipid body formation in 
human  PMN.  (A)  PMN  (10  6 
cells/ml) were treated with PAF 
(10-8-10  -6  M)  (open circle) or 
lyso-PAF  (10-8-10  -6  M)  (solid 
circle) for 1 h at 37~  (B) PMN 
were treated with PAF (1 p~M) at 
37~  Samples were taken at var- 
ious time intervals (5-240 min). 
The open and sohd circles repre- 
sent  PAF  and  vehicle,  respec- 
tively.  Lipid  bodies  were  enu- 
merated  using light  microscopy 
after  osmium  staining.  Each 
point  represents  the  mean  + 
SEM  from  50  consecutively 
counted PMN.  Data  from  one 
individual donor are representa- 
tive  of four to  six  experiments 
with  similar results.  Statistically 
significant  differences  are  indi- 
cated by asterisks. 
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Effect of the PAF receptor antagonist WEB 2086 (WEB) and 
pertussis toxin  (PTX) on PAF-induced lipid body formation in human 
PMN.  PMN  (10  6  cells/ml) were  pretreated with  WEB  2086 (1-100 
b~M), pertussis toxin (100 ng/ml) or vehicle for 1 h at 37~  Cells were 
then treated with PAF (1 IzM) or vehicle for 1 h at 37~  Lipid bodies 
were  enumerated using light microscopy after osmium staining. Each 
point represents the mean + SEM from 50 consecutively counted PMN. 
Data from one individual donor are representative of four experiments 
with similar results. The statistically  significant difference between PAF 
and the vehicle is marked by a cross, whereas differences due to the pre- 
treatment with WEB 2086 or pertussis toxin are indicated by asterisks. 
treatment alone,  NS)  failed to inhibit the increase in lipid 
body numbers  induced by PAF in human  PMN.  In con- 
trast,  several  mechanistically different  inhibitors  of 5-LO 
blocked PAF-induced lipid body formation (Table 2). The 
5-1ipoxygenase-activating  protein (FLAP) antagonist MK886 
(13), the 5-LO inhibitor zileuton (14), and two other lipoxy- 
genase inhibitors, nordihydroguaiaretic acid and diethylcar- 
bamazine, inhibited lipid body formation elicited by PAF. 
To confirm the 5-LO dependence of PAF-induced lipid 
body formation, leukocytes from wild-type and 5-LO knock- 
out  mice  were  studied.  As  with  human  cells,  wild-type 
mouse  PMN  and  macrophages  contain  only  a  few  lipid 
bodies under normal conditions and could be stimulated in 
vitro  to  form  lipid bodies with  PAF  (10-8-10 -c' M),  but 
not with lyso-PAF (10 -6 M)  (Fig. 3 A). In agreement with 
the  results obtained using human  PMN,  MK886  (5  IxM) 
drastically inhibited PAF-induced lipid body formation in 
wild-type mice, whereas aspirin (10  p~g/ml) had no  effect 
(data not shown).  As shown in Fig. 3 A, PAF failed to in- 
duce lipid body formation in both PMN  and macrophages 
from 5-LO knockout animals in all the concentrations ana- 
lyzed. That PAF induction of lipid body formation in leu- 
kocytes occurred  in  vivo as  well as  in  vitro  and  was  also 
requisitely dependent  on  5-LO  activity was  established in 
mice.  Intrathoracic  injection of PAF into  wild-type mice 
induced a drastic increase in the number of lipid bodies in 
resident macrophages  after 4  h  in  comparison  to  the  ani- 
mals that received buffer only (Fig. 3 B). In accord with re- 
sults obtained in vitro, PAF failed to induce lipid body for- 
Table 2.  Effect  of L T Biosynthesis Inhibitors on PAF-induced 
Lipid Body Formation in Human PMN 
Percent 
Treatment  Dose  Lipid bodies  inhibition 
(mean +- SEM)/PMN 
MK 886  0  8.0 _+ 0.1  -- 
2 p,M  5.4 +  0.3*  61 
10 p~M  4.1  _+ 0.3*  93 
Zileuton  0  12.3  _+ 0.4  -- 
0.1  p,M  7.6 +  0.2*  73 
1 ~M  5.2 -+ 0.2*  I00 
NDGA  0  8.9 +  0.4  -- 
10 btM  4.4 -+ 0.3*  61 
20 btM  3.9 +  0.3*  67 
DEC  0  8.9 +  0.4  -- 
5 mM  2.2 -+ 0.3*  90 
PMN  (10  6 cells/ml) were pretreated with MK886, zileuton, nordihy- 
droguaiaretic acid (NDGA), diethylcarbamazine (DEC), or vehicle for 
1 h at 37~  PAF (1 p~M) or vehicle was added, and another incubation 
at 37 ~ C  for 1 h followed. Lipid bodies were enumerated  using light 
microscopy after osmium staining. Each point represents the mean  -+ 
SEM from 50 consecutively counted PMN. Data from one individual 
donor are representative of two to five experiments with similar results. 
Percentage  of inhibition  was calculated using the following formula: 
Percent inhibition  =  100  -  (net no. lipid bodies in treatment  group) 
(100)/(net no. lipid bodies PAF alone). The statistically significant dif- 
ferences caused by pretreatment  with  MK886,  zileuton,  NDGA, and 
DEC are indicated by asterisks. 
mation  in  pleural  resident  macrophages  from  5-LO 
knockout mice  (Fig. 3  B). As shown in Fig. 3  C,  PAF in- 
duced a significant increase in PMN  migration to the pleu- 
ral cavity of wild-type mice  but failed to  attract PMN  to 
the pleural cavity of 5-LO knockout mice. 
The  5-LO  pathway  product  active  in  eliciting  PMN 
lipid body formation was not LTB4. Exogenous LTB 4 was 
not active in stimulating lipid body formation (Table 1). To 
confirm this and to establish that endogenously formed LTB4 
was not involved, an LTB4  receptor agonist,  CP-1"05,696 
(which  inhibits LTB4-induced  PMN  chemotaxis  with  an 
ICs0 of 5.2  nM  [15]),  at 0.1-1  p,M failed to inhibit PAF- 
induced lipid body formation (mean  +  SEM lipid bodies/ 
PMN 7.4 +  0.2 with 1 ~M of CP-105,696 vs. 8.2  +  0.2 for 
vehicle treatment alone, NS).  In contrast,  5-HETE  (10 -9- 
10 -7 M) significantly induced lipid body formation in a dose- 
dependent  way  (Fig.  4  A).  Similar to  PAF-induced lipid 
body formation,  5-HETE-induced  increases in lipid body 
numbers  were  significant within  15  rain,  maximal within 
1-2  h.  and decreased thereafter  (Fig. 4  B). Both  5-HETE 
enantiomers induced lipid body formation; however, 5(S)- 
HETE  was  significantly more potent than  5(R)-HETE  in 
all  concentrations  tested  (Fig.  4).  The  effect  of the  5(S)- 
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Figure 3.  In vitro and in vivo effects of PAF in wild type and 5-LO knockout mice. Effect of PAF on lipid body formation  in peritoneal macrophages 
or bone marrow PMN from wild-type or 5-[.0 knockout mice (A). Macrophages  (drde)  or PMN (square)  (10  ~ cells/ml) were treated with PAP (10 -8- 
10 -6 M) for 1 h at 37~  Lyso-PAF (10 -6 M) is represented by triangles and diamonds in macrophages and PMN, respectively. The open and solid sym- 
bols represent wild-type and 5-LO knockout mice, respectively. Effect of intrathoracic  injection of PAP (1 IJ~g/cavity) (solid columns)  or vehicle (open col- 
umns) on hpid body formation  in resident macrophages (/3) and pleural FMN accumulation  (C) in wild-type or 5-LO  knockout mice. Lipid bodies were 
enumerated in 50 consecutive  cells using hght microscopy  after osmium staining. Each point represents the mean +  SEM from four to seven animals. 
Statistically significant differences are indicated by asterisks. 
HETE  metabolite, 5-oxo-ETE, on lipid body formation was 
also analyzed.  5-oxo=ETE  significantly increased the num- 
ber of lipid bodies in PMN,  with a similar time course ob- 
served for 5(S)-HETE, but with a lesser potency, compara- 
ble  to  5(R)-HETE.  Pretreatment  of PMN  with  the  PAP 
receptor  antagonist  WEB  2086  (mean  +  SEM  lipid bod- 
ies/PMN  8.1  -+  0.2 with  50  ~,M  of WEB  2086  vs. 7.9  -+ 
0.2 for vehicle treatment alone, NS)  and the 5-LO  inhibi- 
tor zileuton  (mean  +  SEM  hpid  bodies/PMN  8.3  -  0.3 
with  0.5  I-tM  of zileuton  vs.  7.9  +  0.2  for vehicle  treat- 
ment  alone,  NS)  failed to  inhibit the lipid body formation 
induced by 5(S)-HETE.  Induction ofhpid body formation 
by 5(S)-HETE, however, was significandy inhibited by per- 
tussis  toxin  (mean  +  SEM  hpid  bodies/PMN  4.5  +  0.2 
with  100 ng/rnl ofpertussis  toxin vs. 7.9  -+  0.2 for vehicle 
treatment  alone,  P  <0.05).  As  shown  in  Fig.  4  C,  5(S)- 
HETE  and  5(R)-HETE  dose-dependently  stimulated lipid 
body  formation  in  bone  marrow  PMN  from  both  wild- 
type  and  5-LO-deficient  mice,  and  no  differences  in  the 
pattern  or intensity of 5-HETE-induced  lipid body forma- 
tion  between  wild-type  and  5-LO--deficient  PMN  were 
noted.  Collectively, these results indicate that 5-HETE,  but 
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Figure 4.  Stimulation  of lipid body formation  by 5(S)-HETE, 5(R)-HETE, and 5-oxo-ETE in human and murine PMN. (A) Dose-dependent lipid 
body formation  induced by 5(S)-HETE, 5(R)-HETE, and 5-oxo-ETE in human PMN.  PMN (10  6 cells/ml)  were treated  with 5(S)-HETE (10 -9- 
10 -7 M) (solid drdes),  5(R)-HETE (10-9--10  -7 M) (open circles), or 5-oxo-ETE (10-9-10 -7 M) (solid  triangles)  for 1 h at 37~  (13) Time-dependent lipid 
body formation  induced  by 5(S)-HETE, 5(R)-HETE, and 5-oxo-ETE in human PMN. PMN were treated  with 5(S)-HETE (10 -7 M)  (solid  circles), 
5(R)-HETE (10 -7 M) (open  circles), 5-oxo-ETE (10 -7 M) (closed triangles)  or vehicle (solid squares)  at 37~  Samples were taken at various time intervals 
(5-240 rain). Each point represents the mean -+ SEM from 50 consecutively counted PMN. Data from one individual donor are representative of two to 
four experiments  with similar results. (C) Effect of 5-HETE on lipid body formation  in hone marrow PMN from wild-type and 5-LO knockout mice. 
PMN (106 cells/m/) were treated with 5(S)-HETE (10-9-10 -v M) (squares)  or 5(R)-HETE (10-9-10 -7 M) (cirdes) for 1 h at 37~  The open and solid 
symbols represent wild-type and 5-LO knockout mice, respectively. Each point represents the mean +  SEM from three animals. Lipid bodies were enu- 
merated using hght microscopy after osmium staining. Statistically significant differences are indicated by asterisks. 
1519  Bozza et al. Table 3.  Effect  of PKC, PLC, and Protein Synthesis lnhibitors on PAl:- and 5(S)-HETE-induced lipid Body Formation 
PAF  5 (S)-HETE 
Percent  Percent 
Treatment  Dose  Lipid bodies  inhibition  Lipid bodies  inhibition 
IzM  (mean + SEM)/PMN  (mean +- SEM)/PMN 
Staurosproine  0  8.5 +  0.3  -  7.8 +  0.3  - 
0.1  6.3 -+ 0.3*  47  6.1  -+ 0.2*  63 
1  5.7 -+ 0.2*  60  5.6 +  0.2*  83 
Chelerythrine  0  7.5 +  0.2  -  7.8 -+ 0.3  - 
0.5  6.7 +  0.2*  22  6.2 -+ 0.3*  61 
1  6.2 _+ 0.2*  46  5.6 -+ 0.3*  84 
U-73122  0  8.5 -+ 0.3  -  7.8 +  0.3  - 
1  6.6 -+ 0.3*  57  6.1  +  0.2*  63 
5  5.8 +  0.2*  80  5.6 +  0.2*  81 
D609  0  8.l  +  0.3  -  7.8 +  0.3  - 
0.1  6.0 -+ 0.2*  59  6.0 -  0.2*  66 
1  5.3  +  0.2*  78  5.3 -+ 0.2*  94 
Actinomycin D  0  8.0 +  0.2  -  7.6 +  0.2  - 
I  4.9 -+ 0.3*  67  4.4 -+ 0.2*  75 
10  4.3 _+ 0.3*  79  3.8 -+ 0.3*  88 
Cycloheximide  0  7.9 +  0.2  -  7.8 -+ 0.3  - 
1  5.8 -+ 0.2*  76  6.6 ~  0.2*  43 
10  5.3 +  0.2*  96  5.4 -+ 0.2*  89 
PMN (106 ml) were pretreated with PKC inhibitors (staurosporine and chelerythrine) or the protein synthesis inhibitor cycloheximide for 30 min 
and with PLC inhibitors (D609 and U-73122)  or the 1KNA synthesis inhibitor actinomycin D for 1 h and then stimulated with PAF (1 ~M), 5(S)- 
HETE (0.1 ~M), or vehicle for 1 h. Results are mean +  SEM from 50 consecutively counted PMN. Data from one individual donor are represen- 
tative of two to four experiments with similar results. Percentage of inhibition was calculated using the following formula: Percent inhibition =  100 - 
(net no. lipid bodies in treatment group) (100)/net  no. lipid bodies in agonist alone). Statistically significant differences between agonists alone and 
treated groups are indicated by asterisks. 
not LTB  4,  mediates PAF-induced hpid body formation in 
leukocytes. 
Effect of PKC, PLC, and Protein Synthesis Inhibition on PAF- 
and 5(S)-HETE-induced Lipid Body Formation.  The mech- 
anisms involved in PAF-induced lipid body formation were 
analyzed. As shown in Table 3,  staurosporine (0.1-1  F~M) 
significantly inhibited the  increase in  lipid body numbers 
induced by PAF and 5(S)-HETE.  In addition, the selective 
PKC inhibitor chelerythrine (0.5-1  btM) also inhibited PAF- 
and  5(S)-HETE-induced  lipid body formation by 46  and 
84%,  respectively, at the  highest  concentration  used,  thus 
implicating PKC  activation in lipid body formation.  It has 
been previously described that PAF-induced PMN  activa- 
tion,  including  chemotaxis  and  superoxide  anion  release, 
depends on PLC activation (16,  17). To determine ifPAF- 
stimulated induction of PMN lipid bodies was mediated by 
PLC  activation, two  PLC inhibitors were  used: U-73122, 
an  inhibitor  of G  protein-mediated PLC  activation  (18), 
and  D609,  a  phosphatidylcholine-PLC inhibitor  (19).  As 
shown in Table 3,  PAF-induced lipid body formation was 
significantly inhibited by 78  and 80% when the cells were 
pretreated with  D609  (1  tzM)  and  U-73122  (5  IxM),  re- 
spectively. Similarly, lipid body induction  by 5(S)-HETE 
was also inhibited by D609 and U-73122  (Table 3). Inhib- 
itors of mRNA  and protein synthesis, actinomycin D  and 
cycloheximide, respectively, almost completely blocked both 
PAF- and 5(S)-HETE-induced lipid body formation. These 
inhibitors did not alter numbers  of preformed lipid bodies 
in PMN,  suggesting that the induction of lipid body for- 
mation  by PAF and  5(S)-HETE  was  dependent  on  gene 
expression and de novo protein synthesis. 
Involvement of Lipid Bodies in PMN Pn'ming  for PGE  2 and 
LTB  4 Production.  We analyzed the effect of increased num- 
bers of  lipid bodies on PGE2 and LTB4 production by human 
PMN. PMN were incubated with increasing concentrations 
of PAF (10-8-10 -6 M) for 5 rain and 1 h. After the incuba- 
tion time, lipid bodies were enumerated, and replicate leu- 
kocytes were stimulated with a submaximal dose of calcium 
ionophore A23187  (0.5 I-tM). As shown in Fig. 5, PAF in- 
duced a dose-dependent increase in the lipid body numbers 
in PMN  after 1 h,  but not as early as 5  rain after stimula- 
tion. The incubation of PMN with PAF for only 5 rain failed 
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Figure 5.  Effect of PAF on lipid body 
formation  and  priming for  LTB4 (A) 
and PGE  z  (B)  production by human 
PMN.  PMN  (10  6  cells/ml  in  5  ml) 
were stimulated by PAF (10-8-10 -6 M) 
for 5 min or 1 h at 37~  for the induc- 
tion of lipid bodies. After this period the 
cells were  incubated with A23187  (0.5 
~M) for 15 min at 37~  for LTB 4 and 
PGE2  production.  Concentrations  of 
LTB  4 and PGE  2 in the supematant were 
assayed by ELISA. Results are mean --- 
SEM from  four to six independent as- 
says. Statistically significant  differences 
are indicated by asterisks. 
to prime PMN for LTB  4 (Fig. 5 A) or PGE  2 (Fig. 5 B) pro- 
duction induced by A23187.  However, after 1 h  of PAF 
stimulation,  a significant and dose-dependent priming for 
both LTB4 (Fig. 5 A) and PGE2 (Fig. 5  B) production was 
noted.  PAF  induced  a  5.5-  and  2.8-fold  increase  in  the 
production of LTB4  or PGE  2,  respectively,  at  the  highest 
PAF concentration (10 -6 M). Furthermore, statistically sig- 
nificant positive correlations between the  content of lipid 
bodies  in  PMN  and  the  priming  for  LTB  4  (r  =  0.986, 
P  <0.001)  and PGE2  (r  =  0.971,  P  <0.001)  release were 
obtained, thus suggesting that lipid bodies may contribute 
to eicosanoid formation in PMN. 
Since the protein synthesis inhibitors actinomycin D  and 
cycloheximide  were  effective  in blocking lipid body for- 
marion induced by PAF, and lipid body numbers correlated 
with  enhanced  eicosanoid  formation,  we  tested  whether 
protein  synthesis  inhibitors  would  inhibit  PAF-induced 
priming for  eicosanoid production.  Pretreatment of PMN 
with actinomycin D  (1  p~M)  or cycloheximide (1  I~M) in- 
hibited  not  only PAF-induced lipid body  formation,  but 
also  "priming"  for  enhanced LTB  4  (Fig.  6  A)  and  PGE  2 
(Fig. 6 B) production. Protein synthesis inhibitors were not 
acting to block pathways of arachidonate release or metab- 
olism that are activated by calcium ionophore, since actino- 
mycin D  and cycloheximide failed to inhibit calcium iono- 
phore-induced  LTB  4  and  PGE  2 production  in  cells  not 
prestimulated with PAF (data not shown). 
Discussion 
Human PMN obtained from healthy donors contain few 
lipid bodies. However, a dramatic increase in lipid body num- 
bers is observed in vivo in blood or tissue PMN when these 
cells  are involved in a variety of infectious, allergic, neo- 
plastic,  and other inflammatory diseases (6, 20). Lipid body 
induction in PMN can also be elicited in vitro, when cells 
are stimulated with cis-unsaturated,  but not fully saturated, 
fatty acids (6, 21). In this study, we showed that stimulation 
of PMN  with PAF leads to rapid (15--60 rain) formation of 
lipid bodies.  Although  PAF  is  a  lipid,  mechanisms  other 
than the  simple incorporation of exogenous lipids are  in- 
volved  in lipid body  formation.  First,  the  PAF  precursor 
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,OAF.. 
+ vehicle 
+ actinomycin D 
+ cycloheximide 
[]  LTB4(ng/106PMN)  []  PGE2(Pg/106PMN) 
0  10  20  30  40  50  0  50  100  150 
I  I  ,I  I 
2  4  6  8 
￿9  Lipid  Bodies/PMN 
A 
1521  Bozza et al. 
10  2  4  8 
￿9  Lipid Bodies/PMN 
200 
B 
10 
Figure  6.  Inhibition of PAF-induced 
lipid  body  formation  and  priming  for 
LTB 4 (/1) and PGE2 (B) production by ac- 
tinomycin D  and  cycloheximide.  PMN 
(106 cells/ml  in  5  ml)  were  pretreated 
with actinomycin D (1 IxM), cyclohexim- 
ide (1 I~M), or vehicle for 30 min at 37~ 
Cells were  then stimulated with PAF  (1 
p,M) or vehicle for 1 h at 37~  for the in- 
duction of lipid bodies. After this period, 
the cells were incubated with A23187 (0.5 
I-~M) for  15 rain at  37~  for  LTB  4  and 
PGE2  production.  Concentrations  of 
LTB 4 and PGE  2 in the supernatant were 
assayed by ELISA. Results  are  mean  + 
SEM from four independent assays. Statis- 
tically significant differences are indicated 
by asterisks. and metabolite, lyso-PAF, that shares the lipid structure of 
PAF but differs by the absence of an acetate group at the 
sn-2 position and has no receptor agonistic activity (for re- 
view see reference 22), lacked the capacity to induce lipid 
body formation. In addition, significant lipid body forma- 
tion  was  induced  by  PAF  at  nanomolar  concentrations, 
consistent with a receptor-dependent phenomenon. In agree- 
ment, PAF-induced lipid body formation was dose depen- 
dently inhibited by the PAF receptor antagonist WEB 2086 
with an approximate ICs0 of 0.4 ~*M. 
The PAF  receptor belongs  to  a  family of seven-trans- 
membrane domain rhodopsin-like G  protein-coupled re- 
ceptors (23). In PMN, PAF has been shown to trigger both 
pertussis-sensitive and -resistant responses, depending upon 
the reaction analyzed. For instance, the chemotactic effect 
of PAF on PMN is sensitive to pertussis  toxin inhibition, 
whereas the calcium influx in response to PAF is resistant  to 
pertussis  toxin (23).  The effect of pertussis  toxin on PAF- 
induced lipid body formation was  analyzed.  Pretreatment 
of PMN  with  pertussis  toxin  completely inhibited  PAF- 
induced lipid body formation, thus suggesting that PAF is 
acting through a pertussis toxin-sensitive G protein to in- 
duce the formation of  lipid bodies. Interestingly, other PMN 
agonists, including LTB4, C5a, FMLP, and IL-8, which also 
signal  through seven-transmembrane spanning G  protein- 
coupled receptors, failed to induce lipid body formation in 
PMN.  Thus,  the  receptor-mediated signaling initiated by 
PAF that leads  to hpid body formation in PMN is specific 
and not common to all PMN agonists that signal  through 
G protein-linked receptors. 
Since increased hpid body formation within cells is asso- 
ciated  with  inflammatory responses  (5,  20),  we  analyzed 
the effects of antiinflammatory drugs on lipid body forma- 
tion. Four structurally unrelated cyclooxygenase inhibitors 
failed to inhibit hpid body induction by PAF,  ruling out 
involvement of cyclooxygenase activation in the process of 
PAF-induced lipid body formation. In contrast, lipid body 
formation induced by cis-unsaturated fatty acids is inhibited 
by nonsteroidal antiinflammatory drugs  including aspirin, 
indomethacin, and sodium salicylate  (Bozza, P.T., and P.F. 
Weller,  unpublished  observations).  These  results  suggest 
that different metabolic pathways may be involved in lipid 
body formation depending on the eliciting stimuli. 
Although PAF may activate inflammatory cells directly, 
several PAF-induced  effects, including  edema  formation, 
PMN migration, pulmonary hypertension, and lethahty, are 
mediated through LT (22). We demonstrated that the spe- 
cific 5-LO inhibitor zileuton (14)  and the FLAP inhibitor 
MK 886  (13)  inhibited lipid body formation induced by 
PAF, suggesting that both FLAP and 5-LO are involved in 
PAF-induced lipid body formation. Recently, the genera- 
tion of LT-deficient mice in which the 5-LO pathway was 
inactivated by the  targeted  disruption  of the  5-LO  gene 
was  described  (11,  24).  Peritoneal macrophages  obtained 
from  5-LO  knockout  animals  have  no  residual  5-LO 
mRNA  or protein  and  are  incapable  of synthesizing LT 
(11,  24).  Interestingly, one feature of the 5-LO knockout 
phenotype is an increased resistance to PAF-induced lethal- 
ity (11,  24). To further evaluate the involvement of 5-LO 
in PAF-induced lipid body formation, we analyzed the ef- 
fect of PAF on peritoneal macrophages and bone marrow 
PMN from wild-type and 5-LO knockout mice. Similar to 
the  results  obtained with  human  PMN,  PMN  and  mac- 
rophages from wild-type mice were dose dependently stim- 
ulated by PAF to induce lipid body formation. However, 
PAF failed to increase lipid body numbers in cells obtained 
from 5-LO knockout mice. Likewise, the capacity of PAF 
to  ehcit lipid  body formation in  vivo was  shown  to  be 
5-LO dependent in studies  with an acute model of inflam- 
mation in mice. The intrathoracic injection of PAF signifi- 
candy increased the number of lipid bodies in pleural resi- 
dent macrophages (Fig. 3) and in the PMN that migrated to 
the pleural cavity (data  not shown)  from wild-type mice, 
but  failed to stimulate  pleural macrophages  or PMN  from 
5-LO knockout mice. These findings indicate the requisite 
role for 5-LO activity in the in vitro and in vivo induction 
of  leukocyte hpid bodies by PAF. 
Among the metabolites of the  5-LO pathway, LTB  4 is 
the most potent activator of human PMN. In PMN, LTB  4 
mediates different functions including adhesion, chemotaxis, 
and aggregation, and high levels of  LTB4 can be detected in 
fluids  from  inflammatory  and  allergic  reactions  (1,  25). 
Thus, LTB4 would be a likely candidate to mediate PAF- 
induced lipid body formation in PMN. Nevertheless, LTB  4 
itself failed to induce lipid body formation in human PMN 
(Table 1). Moreover, the specific LTB  4 receptor antagonist 
CP-105,696 (15) had no inhibitory effect on PAF-induced 
lipid body formation, excluding a role for both exogenous 
and endogenous LTB  4 as a mediator of PAF-induced lipid 
body formation. Another PMN activator derived from the 
5-LO pathway is 5(S)-HETE (26,  27). Lipid body forma- 
tion  in  human  PMN  was  dose  dependently induced  by 
both R  and S isomers of 5-HETE (Fig.  4 A). Dose- and 
time-response  curves for hpid  body induction  stimulated 
by  both  isomers  had  the  same  shapes;  however,  5(S)- 
HETE was more potent than 5(R)-HETE (Fig.  4, A  and 
B).  These results  are in agreement with previous findings 
that  demonstrate  that  5(S)-HETE  is  more  potent  than 
5(R)-HETE in mobihzing Ca  2+  in human PMN and also 
in "priming" PMN to degranulate in response to PAF and 
diacylglycerol (28,  29). Recently, a novel pathway for the 
metabolization of S(S)-HETE in PMN resulting in the for- 
mation of 5-oxo-ETE was described (30).  5-oxo-ETE was 
shown to stimulate PMN in a LTB4-independent manner, 
but  seems  to  use  the  same  putative  receptor as  5-HETE 
(31).  In accordance, 5-oxo-ETE dose dependently stimu- 
lated human PMN to form lipid bodies (Fig. 4), but with a 
lesser potency than 5(S)-HETE. 5-HETE could bypass the 
5-LO  deficiency in  5-LO knockout mice  and stimulated 
PMN  from both wild-type and  5-LO  knockout mice  to 
form hpid bodies (Fig. 4 C). Since PAF-induced lipid body 
formation is 5-LO dependent and is elicited not by LTB  4 
but by 5(S)-HETE, which is active at 10 times lower con- 
centrations than PAF itself to induce comparable numbers 
of lipid bodies, endogenously formed 5(S)-HETE mediates 
PAF-induced lipid body formation. 
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not clearly understood. Although 5-HETE is able to stimu- 
late PMN at nanomolar concentrations, in a stereospecific and 
G protein-dependent way, putative receptors for 5-HETE 
have not yet been identified (29).  Receptor-independent 
mechanisms  of action for  5-HETE  have  been proposed. 
Moreover, PMN have an enormous capacity to incorpo- 
rate HETEs into their phospholipids and triglycerides (32), 
and such effects might contribute to lipid body formation. 
Nevertheless, since the induction of hpid bodies in PMN 
by 5(S)-HETE occurs at nanomolar concentrations of 5(S)- 
HETE, is inhibited by pertussis toxin, suggesting the involve- 
ment of a pertussis  toxin-sensitive G protein, and is depen- 
dent on PKC and PLC activation, it is hkely that a 5-HETE 
receptor is involved in signaling lipid body formation. 
We  further  investigated  other  signaling  pathways  that 
could contribute to PAF- and 5-HETE-induced lipid body 
formation. It has been shown in several cells that respond 
to PAF, including human PMN, that PAF transmembrane 
signaling  is  related to  an increased turnover of phospho- 
inositide  due  to  PLC  activation  (23,  33).  Accordingly, 
PAF- and 5-HETE-induced lipid body formation was in- 
hibited by two PLC inhibitors, D609  and U-73122,  thus 
suggesting  a  role for PLC in  this  reaction.  The products 
generated by the action of PLC on phosphohpids, inositol 
triphosphate and diacylglycerol, are involved in the release 
of Ca  2§  from the endoplasmic reticulum and PKC activa- 
tion (34).  The effect of two PKC inhibitors, staurosporine 
and chelerythrine, on PAF-stimulated hpid body formation 
were observed (Table 3). The ability of the PKC inhibitor 
staurosporine  to  block hpid  body  formation  induced  by 
PAF and 5-HETE suggests  the involvement of PKC acti- 
vation in this process.  However, the selectivity of stanro- 
sporine as a PKC inhibitor has been questioned (35), and at 
concentrations  used  in  these  experiments,  staurosporine 
would  also  inhibit  tyrosine  protein  kinase,  calcium/cal- 
modulin-dependent protein kinase, and cAMP-dependent 
protein kinase (35,  36). To better address the role of PKC 
on hpid body formation, a highly selective PKC inhibitor 
was used. Chelerythrine is a potent and selective PKC in- 
hibitor that interacts with the catalytic domain of PKC and 
is devoid of effect on other protein kinases  (36).  In our ex- 
periments, a similar degree of inhibition of hpid body for- 
mation was observed for treatments with staurosporine and 
chelerythrine, 66 and 46%, respectively, which is consistent 
with involvement of PKC in PAF-induced lipid body for- 
mation.  In  support  of the  involvement of PKC  in  lipid 
body formation, it was previously demonstrated that direct 
PKC  activators  including  1-oleoyl-2-acetyl-glycerol and 
two active phorbol esters (PMA and phorbol 12,  13 dibu- 
tyrate) effectively induced lipid body formation in human 
PMN (21).  The formation of lipid bodies in PMN, stimu- 
lated by PAF  and  5(S)-HETE, requires  de  novo protein 
synthesis and was  almost fully inhibited  by inhibition  of 
R.NA synthesis with actinomycin D  and protein synthesis 
with cycloheximide (Table 3). Thus, it is likely that specific 
early response  genes  are  activated  and  participate  in  the 
metabolic processes that lead to lipid body formation. 
Under normal circumstances, leukocytes stimulated with 
receptor-mediated stimuli,  including PAF  and  FMLP,  or 
with submaximal concentrations of calcium ionophore gen- 
erate litde  or undetectable  amounts  of eicosanoids unless 
the  cells  are first  primed  (37,  38).  Priming is  therefore a 
critical step in the activation of PMN during inflammation 
and has  been the  subject of several investigations.  How- 
ever, the biochemical alterations and physiological site  of 
priming remain unclear. It is interesting to note that prim- 
ing  agents  for PMN-induced  eicosanoid production,  in- 
cluding 1-oleoyl-2-acetyl-glycerol, arachidonate, and PAF, 
in the concentrations and time period used (37, 39) are also 
active in stimulating lipid body formation (21,  Fig. 1). Ac- 
cordingly, in this study we observed a significant correla- 
tion between lipid body formation induced by PAF  and 
priming for PGE2 and LTB  4 production in PMN  stimu- 
lated  by  submaximal  concentrations  of  the  ionophore 
A23187  (Fig.  5).  Furthermore, pretreatment of cells  with 
actinomycin D  or cycloheximide inhibited not only the in- 
duction of lipid body formation by PAF, but also the PAF- 
induced priming for enhanced PGE  2 and LTB  4 in PMN, 
suggesting that lipid bodies are early response structures in- 
volved in the production of hpid mediators of inflamma- 
tion. 
Together with  the  findings  that  lipid  bodies  store  the 
eicosanoid  precursor  arachidonate  esterified  in  specific 
phospholipids (6, 7) and also may contain the key enzymes 
for  eicosanoid metabohzation  (8-10),  our  results  suggest 
that lipid bodies are specialized, inducible intracellular do- 
mains involved in the metabolic generation of eicosanoids 
during the inflammatory process. 
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